ロード中...
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that is expressed on tumor cells that suppresses the T cell-mediated immune response. Therapies targeting the PD-L1 pathway promote anti-tumor immunity and have shown promising results in some types of cancers. However, the functional...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5444742/ https://ncbi.nlm.nih.gov/pubmed/28415820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16326 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|